PLSE vs. OFIX, IRMD, SRDX, SIBN, BVS, FNA, ANIK, NVRO, OSUR, and CERS
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Orthofix Medical (OFIX), Iradimed (IRMD), Surmodics (SRDX), SI-BONE (SIBN), Bioventus (BVS), Paragon 28 (FNA), Anika Therapeutics (ANIK), Nevro (NVRO), OraSure Technologies (OSUR), and Cerus (CERS). These companies are all part of the "surgical & medical instruments" industry.
Pulse Biosciences (NASDAQ:PLSE) and Orthofix Medical (NASDAQ:OFIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
Pulse Biosciences has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Pulse Biosciences has higher earnings, but lower revenue than Orthofix Medical. Pulse Biosciences is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pulse Biosciences had 7 more articles in the media than Orthofix Medical. MarketBeat recorded 10 mentions for Pulse Biosciences and 3 mentions for Orthofix Medical. Pulse Biosciences' average media sentiment score of 1.19 beat Orthofix Medical's score of 0.93 indicating that Pulse Biosciences is being referred to more favorably in the media.
Orthofix Medical received 164 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 61.80% of users gave Orthofix Medical an outperform vote.
76.9% of Pulse Biosciences shares are held by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are held by institutional investors. 71.5% of Pulse Biosciences shares are held by company insiders. Comparatively, 4.7% of Orthofix Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Pulse Biosciences has a net margin of 0.00% compared to Orthofix Medical's net margin of -16.64%. Orthofix Medical's return on equity of -14.24% beat Pulse Biosciences' return on equity.
Orthofix Medical has a consensus target price of $18.00, indicating a potential upside of 23.12%. Given Orthofix Medical's higher possible upside, analysts clearly believe Orthofix Medical is more favorable than Pulse Biosciences.
Summary
Pulse Biosciences beats Orthofix Medical on 9 of the 17 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
